FULGENT GENETICS, INC. |
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
| 20.21 USD | +0.50% |
|
-2.60% | -29.99% |
Presenter SpeechDaniel Leonard (Analysts)Great. Well, welcome, everybody, to the Credit Suisse...
This article is reserved for subscribers
Signed up already?
Log InNot subscribed yet?
Subscribe
Fulgent Genetics, Inc. is a technology-based genetic company with a laboratory services business and a therapeutic development business. The Companyâs laboratory services business includes technical laboratory services and professional interpretation of laboratory results by licensed physicians. Its therapeutic development business is focused on developing drug candidates for treating a range of cancers using a nanoencapsulation and targeted therapy platform designed to improve the therapeutic window and pharmacokinetic profile (PK) profile of new and existing cancer drugs. Its technology platform for its laboratory services business includes gene probes, data suppression and comparison algorithms, learning software, and laboratory information management systems. The platform provides a test menu, the ability to rapidly develop and launch new tests and customizable test offerings. The Company also offers next-generation sequencing (NGS) services.
Calendar
2024-05-03
- Q1 2024 Earnings Release
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
C-
Sell
Buy
Mean consensus
HOLD
Number of Analysts
3
Last Close Price
20.11
USD
Average target price
26.67
USD
Spread / Average Target
+32.60%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -29.99% | 601M | |
| -18.11% | 8.02B | |
| +33.36% | 3.51B | |
| -29.02% | 2.97B | |
| -7.71% | 2.48B | |
| -14.30% | 2.23B | |
| -16.35% | 1.76B | |
| -22.56% | 1.44B | |
| -39.69% | 1.25B | |
| -11.20% | 1.11B |
- Stock Market
- Equities
- FLGT Stock
- News Fulgent Genetics, Inc.
- Transcript : Fulgent Genetics, Inc. Presents at Credit Suisse 31st Annual Healthcare Conference, Nov-08-2022 08
